Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation
Matilde Ørum, Frederikke F. Rönsholt, Majbritt Jeppesen, Elisabeth Bendstrup, Terese L. Katzenstein, Peter Ott, Michael Perch, Tacjana Pressler, Tavs Qvist, Søren Jensen‐Fangel
Abstract
We report a case series of four patients with cystic fibrosis (CF) and previous solid organ transplantation (SOT) receiving elexacaftor/tezacaftor/ivacaftor therapy for 6 months or more. Data was collected retrospectively. The treatment was well tolerated and all patients reported subjective improvements.
Topics & Concepts
IvacaftorMedicineCystic fibrosisTransplantationOrgan transplantationLung transplantationIntensive care medicineInternal medicineCystic fibrosis transmembrane conductance regulatorCystic Fibrosis Research AdvancesTracheal and airway disordersNeonatal Respiratory Health Research